Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. | AIDS;21(2): 179-85, 2007 Jan 11. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.

Naeger, Lisa K; Struble, Kimberly A.

Affiliation

Naeger LK; Division of Antiviral Products, Center for New Drug Evaluation, Food and Drug Administration, Silver Spring, Maryland, USA. lisa.naeger@fda.hhs.gov

AIDS ; 21(2): 179-85, 2007 Jan 11.

Article in En | MEDLINE | ID: mdl-17197808

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Pyrones / HIV Infections / HIV-1 / Anti-HIV Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2007 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Pyrones / HIV Infections / HIV-1 / Anti-HIV Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2007 Document type: Article Affiliation country: Country of publication: